THE SHARE: Change: -0.01 SEK (-0.73%) / Price: 0.82 SEK / Jan 27, 2023, 6:00 pm (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • EPR Effect
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

  • 12 Jan, 2023
    Spago Nanomedical publishes positive preclinical data – BioStock
  • 8 Dec, 2022
    Spago Nanomedical starts phase IIa study in endometriosis – BioStock
  • 13 Sep, 2022
    Spago Nanomedical in hot area – BioStock
  • 26 Aug, 2022
    Spago Nanomedical on the autumn newsflow – BioStock
  • 5 Jul, 2022
    Spago Nanomedical progresses towards clinical phase with Tumorad – Biostock
  • 21 Jun, 2022
    Spago Nanomedical tar kliv med kapitalinjektion – Biostock
  • 14 Jun, 2022
    Spago Nanomedical mot klinik med tydlig plan – Biostock
  • 3 May, 2022
    Spago Nanomedical on project potential – Biostock
  • 8 Feb, 2022
    Sapgo Nanomedical looks ahead – Biostock
  • 28 Jan, 2022
    Spago Nanomedical on the progress with Tumorad – Biostock
  • 1
  • 2
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2023 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications